Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
R Todd StravitzMichelle GottfriedValerie DurkalskiRobert J FontanaA James HanjeDavid KochBilal HameedDaniel GangerRam M SubramanianStan BukofzerWilliam R RavisKristen ClasenAverell SherkerLanna LittleWilliam M Leenull nullPublished in: Hepatology (Baltimore, Md.) (2018)
OPA was well-tolerated in patients with ALI/ALF, and no safety signals were identified. Target [PA] was achieved at infusion rates of 20 g every 24 hours, leading to ammonia excretion in urine as PAGN in proportion to renal function. Randomized, controlled studies of high-dose OPA are needed to determine its use as an ammonia-scavenging agent in patients with ALF. (Hepatology 2018;67:1003-1013).